{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:52:58Z","timestamp":1791478378690,"version":"4.3.4"},"reference-count":91,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004331","name":"Janssen Global Services LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology, Transfusion and Cell Therapy"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.htct.2026.106482","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T12:33:07Z","timestamp":1780403587000},"page":"106482","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Brazilian consensus recommendations on the diagnosis and treatment of light chain amyloidosis"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7975-6932","authenticated-orcid":false,"given":"Pedro Manoel Marques","family":"Garibaldi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2641-1425","authenticated-orcid":false,"given":"Jo\u00e3o Tadeu Damian","family":"Souto Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7432-3732","authenticated-orcid":false,"given":"Roberto Jose Pessoa","family":"de Magalh\u00e3es Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5254-3486","authenticated-orcid":false,"given":"Roberta Shcolnik","family":"Szor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2999-1997","authenticated-orcid":false,"given":"Carlos Eduardo","family":"Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8599-4731","authenticated-orcid":false,"given":"Edvan","family":"Crusoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9190-5339","authenticated-orcid":false,"given":"Carolina Tosin","family":"Bueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thiago","family":"Queiroz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4327-1957","authenticated-orcid":false,"given":"V\u00e2nia","family":"Hungria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.htct.2026.106482_bib0001","doi-asserted-by":"crossref","first-page":"27","DOI":"10.14797\/mdcvj.1070","article-title":"Light Chain amyloidosis: epidemiology, staging, and prognostication","volume":"18","author":"Baker","year":"2022","journal-title":"Methodist Debakey Cardiovasc J"},{"issue":"4","key":"10.1016\/j.htct.2026.106482_bib0002","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/13506129.2024.2405948","article-title":"Amyloid nomenclature 2024: update, novel proteins, and recommendations by the international society of amyloidosis (ISA) nomenclature committee","volume":"31","author":"Buxbaum","year":"2024","journal-title":"Amyloid"},{"issue":"4","key":"10.1016\/j.htct.2026.106482_bib0003","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1177\/0300060518814337","article-title":"Multiorgan involvement by amyloid light chain amyloidosis","volume":"47","author":"Li","year":"2019","journal-title":"J Int Med Res"},{"issue":"23","key":"10.1016\/j.htct.2026.106482_bib0004","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1182\/blood.2020006913","article-title":"Management of AL amyloidosis in 2020","volume":"136","author":"Palladini","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.htct.2026.106482_bib0005","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1002253","article-title":"Localized light chain amyloidosis: a self-limited plasmacytic B-cell lymphoproliferative disorder","volume":"12","author":"Martinez","year":"2022","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.htct.2026.106482_bib0006","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jaccao.2022.08.009","article-title":"Amyloidosis for cardiologists: awareness, diagnosis, and Future prospects: JACC: CardioOncology State-of-the-art review","volume":"4","author":"Wechalekar","year":"2022","journal-title":"JACC CardioOncol"},{"issue":"5","key":"10.1016\/j.htct.2026.106482_bib0007","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41408-021-00486-4","article-title":"Comprehensive review of AL amyloidosis: some practical recommendations","volume":"11","author":"Al Hamed","year":"2021","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.htct.2026.106482_bib0008","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-018-0034-3","article-title":"Systemic immunoglobulin light chain amyloidosis","volume":"4","author":"Merlini","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"8","key":"10.1016\/j.htct.2026.106482_bib0009","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41408-021-00529-w","article-title":"Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study","volume":"11","author":"Staron","year":"2021","journal-title":"Blood Cancer J"},{"issue":"19","key":"10.1016\/j.htct.2026.106482_bib0010","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1182\/blood-2011-10-384768","article-title":"Progression in smoldering Waldenstrom macroglobulinemia: long-term results","volume":"119","author":"Kyle","year":"2012","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.htct.2026.106482_bib0011","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1056\/NEJMra2412716","article-title":"Monoclonal gammopathy of undetermined significance","volume":"393","author":"Rajkumar","year":"2025","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.htct.2026.106482_bib0012","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1001\/jamaoncol.2025.1285","article-title":"New definition of light chain monoclonal gammopathy of undetermined significance","volume":"11","author":"Einarsson Long","year":"2025","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.htct.2026.106482_bib0013","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2025017073","article-title":"American Society of Hematology (ASH) 2026 guidelines on diagnosis of light chain amyloidosis","author":"Kukreti","year":"2026","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.htct.2026.106482_bib0014","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.jaccao.2025.07.012","article-title":"Diagnostic performance of the new free light chain ratio in systemic amyloidosis","volume":"7","author":"Milani","year":"2025","journal-title":"JACC CardioOncol"},{"issue":"4","key":"10.1016\/j.htct.2026.106482_bib0015","doi-asserted-by":"crossref","first-page":"444","DOI":"10.2174\/0115748863264472231227060926","article-title":"Cardiac toxicity in the treatment of light chain amyloidosis: systematic review of Clinical Studies","volume":"19","author":"Jattin-Balc\u00e1zar","year":"2024","journal-title":"Curr Drug Saf"},{"issue":"4","key":"10.1016\/j.htct.2026.106482_bib0016","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/ejh.13679","article-title":"Diagnostic delay and characterization of the clinical prodrome in AL amyloidosis among 1523 US adults diagnosed between 2001 and 2019","volume":"107","author":"Hester","year":"2021","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.htct.2026.106482_bib0017","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bbapap.2005.08.014","article-title":"Clinical aspects of systemic amyloid diseases","volume":"1753","author":"Obici","year":"2005","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.htct.2026.106482_bib0018","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/ajh.70246","article-title":"Immunoglobulin light chain amyloidosis: 2026 update on diagnosis, prognosis, and treatment","volume":"101","author":"Gertz","year":"2026","journal-title":"Am J Hematol"},{"issue":"S1","key":"10.1016\/j.htct.2026.106482_bib0019","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.5045\/br.2020.S009","article-title":"Advances in diagnosis and management","volume":"55","author":"amyloidosis","year":"2020","journal-title":"Blood Res"},{"issue":"5","key":"10.1016\/j.htct.2026.106482_bib0020","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/bjh.16096","article-title":"Ten-year survivors in AL amyloidosis: characteristics and treatment pattern","volume":"187","author":"Muchtar","year":"2019","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.htct.2026.106482_bib0021","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/bjh.16143","article-title":"A 24-year experience of autologous stem cell transplantation for light chain amyloidosis patients in the United Kingdom","volume":"187","author":"Sharpley","year":"2019","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.htct.2026.106482_bib0022","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1007\/s11136-023-03354-9","article-title":"A cross-sectional study of patient-reported outcomes and symptom burden using PROMIS and PRO-CTCAE measures in light chain amyloidosis","volume":"32","author":"D'Souza","year":"2023","journal-title":"Qual Life Res"},{"issue":"1","key":"10.1016\/j.htct.2026.106482_bib0023","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s13023-022-02414-6","article-title":"Global epidemiology of amyloid light-chain amyloidosis","volume":"17","author":"Kumar","year":"2022","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"10.1016\/j.htct.2026.106482_bib0024","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jaccao.2021.06.001","article-title":"Amyloid cardiomyopathy: establishing a patient referral center in Brazil","volume":"3","author":"Szor","year":"2021","journal-title":"JACC CardioOncol"},{"issue":"1","key":"10.1016\/j.htct.2026.106482_bib0025","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1186\/s13023-022-02584-3","article-title":"Systemic amyloidosis journey from diagnosis to outcomes: a twelve-year real-world experience of a single center in a middle-income country","volume":"17","author":"Szor","year":"2022","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"10.1016\/j.htct.2026.106482_bib0026","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1200\/OP.22.00396","article-title":"Diagnostic and treatment strategies for AL amyloidosis in an era of therapeutic innovation","volume":"19","author":"Dima","year":"2023","journal-title":"JCO Oncol Pr"},{"issue":"4","key":"10.1016\/j.htct.2026.106482_bib0027","doi-asserted-by":"crossref","first-page":"147","DOI":"10.14740\/jh866","article-title":"Current updates on the management of AL amyloidosis","volume":"10","author":"Elsayed","year":"2021","journal-title":"J Hematol"},{"issue":"2","key":"10.1016\/j.htct.2026.106482_bib0028","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/bjh.13155","article-title":"Guidelines on the management of AL amyloidosis","volume":"168","author":"Wechalekar","year":"2015","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.htct.2026.106482_bib0029","doi-asserted-by":"crossref","first-page":"601","DOI":"10.47102\/annals-acadmedsg.2023101","article-title":"AL amyloidosis: Singapore myeloma study group consensus guidelines on diagnosis, treatment and management","volume":"52","author":"Tan","year":"2023","journal-title":"Ann Acad Med Singap"},{"issue":"2","key":"10.1016\/j.htct.2026.106482_bib0030","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/bjh.13156","article-title":"Guidelines on the diagnosis and investigation of AL amyloidosis","volume":"168","author":"Gillmore","year":"2015","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.htct.2026.106482_bib0031","first-page":"655","article-title":"How to use the nominal group and Delphi techniques","volume":"38","author":"McMillan","year":"2016","journal-title":"Int J Clin Pharm"},{"issue":"6","key":"10.1016\/j.htct.2026.106482_bib0032","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.mayocp.2021.03.012","article-title":"Treatment of AL amyloidosis: mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus statement 2020 update","volume":"96","author":"Muchtar","year":"2021","journal-title":"Mayo Clin Proc"},{"issue":"25","key":"10.1016\/j.htct.2026.106482_bib0033","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1200\/JCO.2013.50.0892","article-title":"Increased serum free light chains precede the presentation of immunoglobulin light chain amyloidosis","volume":"32","author":"Weiss","year":"2014","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.htct.2026.106482_bib0034","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40271-017-0273-5","article-title":"Light chain (AL) amyloidosis: the journey to diagnosis","volume":"11","author":"McCausland","year":"2018","journal-title":"Patient"},{"issue":"1","key":"10.1016\/j.htct.2026.106482_bib0035","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41408-024-01040-8","article-title":"Timing and co-occurrence of symptoms prior to a diagnosis of light chain (AL) amyloidosis","volume":"14","author":"Singh","year":"2024","journal-title":"Blood Cancer J"},{"issue":"9","key":"10.1016\/j.htct.2026.106482_bib0036","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1016\/j.mayocp.2020.06.029","article-title":"Amyloid typing by mass spectrometry in clinical practice: a comprehensive review of 16,175 samples","volume":"95","author":"Dasari","year":"2020","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1016\/j.htct.2026.106482_bib0037","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2018.022","article-title":"Light chain amyloidosis","volume":"10","author":"Milani","year":"2018","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"4","key":"10.1016\/j.htct.2026.106482_bib0038","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1159\/000506617","article-title":"When to suspect a diagnosis of amyloidosis","volume":"143","author":"Vaxman","year":"2020","journal-title":"Acta Haematol"},{"issue":"2","key":"10.1016\/j.htct.2026.106482_bib0039","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/ajh.27545","article-title":"Feasibility of a biomarker-based screening for pre-symptomatic AL amyloidosis in patients with intermediate\/high-risk MGUS","volume":"100","author":"Mangiacavalli","year":"2025","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.htct.2026.106482_bib0040","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000454","article-title":"Systemic AL amyloidosis: current approaches to diagnosis and management","volume":"4","author":"Fotiou","year":"2020","journal-title":"Hemasphere"},{"issue":"1","key":"10.1016\/j.htct.2026.106482_bib0041","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20181415","article-title":"Congo red and amyloids: history and relationship","volume":"39","author":"Yakupova","year":"2019","journal-title":"Biosci Rep"},{"issue":"24","key":"10.1016\/j.htct.2026.106482_bib0042","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1093\/eurheartj\/ehx047","article-title":"Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis","volume":"38","author":"Quarta","year":"2017","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.htct.2026.106482_bib0043","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2025.2453088","article-title":"Bleeding risk and prediction model to predict bleeding risk of tissue biopsy for definitive diagnosis in patients with suspected amyloidosis","volume":"57","author":"Uraiwan","year":"2025","journal-title":"Ann Med"},{"issue":"2","key":"10.1016\/j.htct.2026.106482_bib0044","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/13506129.2025.2462992","article-title":"Global patterns of amyloid typing: results of a survey by the international society of amyloidosis (ISA)","volume":"32","author":"Naiki","year":"2025","journal-title":"Amyloid"},{"issue":"24","key":"10.1016\/j.htct.2026.106482_bib0045","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.htct.2026.106482_bib0046","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jaccao.2021.09.003","article-title":"AL amyloidosis: current chemotherapy and Immune therapy treatment strategies: JACC: CardioOncology State-of-the-art review","volume":"3","author":"Bianchi","year":"2021","journal-title":"JACC CardioOncol"},{"issue":"15","key":"10.1016\/j.htct.2026.106482_bib0047","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1182\/bloodadvances.2024015528","article-title":"Predictive value of free light chain burden in patients with AL amyloidosis treated with bortezomib-based regimens","volume":"9","author":"Saunders","year":"2025","journal-title":"Blood Adv"},{"issue":"24","key":"10.1016\/j.htct.2026.106482_bib0048","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMra2304088","article-title":"Systemic light chain amyloidosis","volume":"390","author":"Sanchorawala","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.htct.2026.106482_bib0049","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.jcmg.2024.10.011","article-title":"The last decade in cardiac amyloidosis: advances in understanding pathophysiology, diagnosis and quantification, prognosis, treatment strategies, and monitoring response","volume":"18","author":"Fontana","year":"2025","journal-title":"JACC Cardiovasc Imaging"},{"issue":"Supplement 1","key":"10.1016\/j.htct.2026.106482_bib0050","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1182\/blood-2024-203527","article-title":"Defining a new \u201cMayo Stage IIIc\u201d ultra poor risk category in systemic AL amyloidosis: incorporating echocardiographic global longitudinal strain to the European modified mayo staging system","volume":"144","author":"Khwaja","year":"2024","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.htct.2026.106482_bib0051","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1080\/13506129.2025.2570096","article-title":"A collaborative approach to amyloidosis and a multidisciplinary care framework - position statement from the International Society of Amyloidosis","volume":"32","author":"Sanchorawala","year":"2025","journal-title":"Amyloid"},{"issue":"1","key":"10.1016\/j.htct.2026.106482_bib0052","doi-asserted-by":"crossref","DOI":"10.1080\/16078454.2022.2157581","article-title":"Assessing the prognostic utility of hematologic response for overall survival in patients with newly diagnosed AL amyloidosis: results of a meta-analysis","volume":"28","author":"Kastritis","year":"2023","journal-title":"Hematology"},{"issue":"7","key":"10.1016\/j.htct.2026.106482_bib0053","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1200\/JCO.22.00643","article-title":"Graded cardiac response criteria for patients with systemic light chain amyloidosis","volume":"41","author":"Muchtar","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.htct.2026.106482_bib0054","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1001\/jamaoncol.2024.2629","article-title":"Graded organ response and progression criteria for kidney immunoglobulin light chain amyloidosis","volume":"10","author":"Muchtar","year":"2024","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.htct.2026.106482_bib0055","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/ajh.23898","article-title":"Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis","volume":"90","author":"Kaufman","year":"2015","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.htct.2026.106482_bib0056","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1182\/blood-2005-11-4385","article-title":"Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL","volume":"107","author":"Palladini","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.htct.2026.106482_bib0057","doi-asserted-by":"crossref","DOI":"10.1155\/ah\/7280805","article-title":"AL amyloidosis: current treatment and outcomes","volume":"2025","author":"Locke","year":"2025","journal-title":"Adv Hematol"},{"key":"10.1016\/j.htct.2026.106482_bib0058","unstructured":"US Food & Drug Administration. FDA grants accelerated approval to Darzalex Faspro for newly diagnosed light chain amyloidosis 2021 [Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-darzalex-faspro-newly-diagnosed-light-chain-amyloidosis]."},{"issue":"17","key":"10.1016\/j.htct.2026.106482_bib0059","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1056\/NEJM199704243361702","article-title":"A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine","volume":"336","author":"Kyle","year":"1997","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.htct.2026.106482_bib0060","doi-asserted-by":"crossref","first-page":"469","DOI":"10.3816\/CLML.2010.n.081","article-title":"Oral cyclic melphalan and dexamethasone for patients with AL amyloidosis","volume":"10","author":"Sanchorawala","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"28","key":"10.1016\/j.htct.2026.106482_bib0061","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1200\/JCO.20.01285","article-title":"Bortezomib, Melphalan, and dexamethasone for light-chain amyloidosis","volume":"38","author":"Kastritis","year":"2020","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.htct.2026.106482_bib0062","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1182\/blood-2024-205077","volume":"144","author":"Kastritis","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.htct.2026.106482_bib0063","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.htct.2026.106482_bib0064","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/ajh.27177","article-title":"Immunoglobulin light chain amyloidosis: 2024 update on diagnosis, prognosis, and treatment","volume":"99","author":"Gertz","year":"2024","journal-title":"Am J Hematol"},{"issue":"19","key":"10.1016\/j.htct.2026.106482_bib0065","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1182\/blood.2020008737","article-title":"How I treat AL amyloidosis","volume":"139","author":"Palladini","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.htct.2026.106482_bib0066","unstructured":"Janssen. Dalinvi\u00ae SC - Identifica\u00e7\u00e3o do produto 2026 [Available from: https:\/\/assets.jnjlabels.com\/innovativemedicine\/latam\/brasil\/dalinvi-sc-vps.pdf]."},{"issue":"1","key":"10.1016\/j.htct.2026.106482_bib0067","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2021.2002841","article-title":"Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines","volume":"29","author":"Sanchorawala","year":"2022","journal-title":"Amyloid"},{"issue":"16","key":"10.1016\/j.htct.2026.106482_bib0068","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1182\/bloodadvances.2025016586","article-title":"From CyBorD to dara-CyBorD, ASCT utilization trends in AL amyloidosis: a 15-year analysis","volume":"9","author":"Muchtar","year":"2025","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.htct.2026.106482_bib0069","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000681","article-title":"Summary of the EHA-ISA Working Group guidelines for high-dose chemotherapy and stem cell transplantation for systemic AL amyloidosis","volume":"6","author":"Sanchorawala","year":"2022","journal-title":"Hemasphere"},{"issue":"8","key":"10.1016\/j.htct.2026.106482_bib0070","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41408-022-00714-5","article-title":"Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through The international kidney and monoclonal gammopathy research group","volume":"12","author":"Havasi","year":"2022","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.htct.2026.106482_bib0071","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/TP.0000000000002813","article-title":"Amyloidosis diagnosed in solid organ transplant recipients","volume":"104","author":"Sharpley","year":"2020","journal-title":"Transplantation"},{"key":"10.1016\/j.htct.2026.106482_bib0072","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2024.101207","article-title":"Current status and prospect of anti-amyloid fibril therapy in AL amyloidosis","volume":"66","author":"Wang","year":"2024","journal-title":"Blood Rev"},{"key":"10.1016\/j.htct.2026.106482_bib0073","unstructured":"AstraZeneca. Update on CARES phase III clinical programme of anselamimab in light chain amyloidosis 2025 [Available from: https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2025\/update-on-anselamimab-in-al-amyloidosis.html]."},{"key":"10.1016\/j.htct.2026.106482_bib0074","unstructured":"Prothena. Prothena announces phase 3 AFFIRM-AL clinical trial for Birtamimab in patients with AL amyloidosis did not meet primary endpoint 2025 [Available from:https:\/\/s201.q4cdn.com\/351053094\/files\/doc_news\/Prothena-Announces-Phase-3-AFFIRM-AL-Clinical-Trial-for-Birtamimab-in-Patients-with-AL-Amyloidosis-Did-Not-Meet-Primary-Endpoint-2025.pdf] ."},{"issue":"1","key":"10.1016\/j.htct.2026.106482_bib0075","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/s41375-021-01317-y","article-title":"A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis","volume":"36","author":"Dispenzieri","year":"2022","journal-title":"Leukemia"},{"issue":"16","key":"10.1016\/j.htct.2026.106482_bib0076","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1182\/blood.2025028383","article-title":"Safety and efficacy of elranatamab in patients with relapsed and\/or refractory immunoglobulin light-chain amyloidosis","volume":"146","author":"Vianna","year":"2025","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.htct.2026.106482_bib0077","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1200\/JCO-24-02252","article-title":"Efficacy and safety of anti-B-cell maturation antigen chimeric antigen receptor T-cell for the treatment of relapsed and refractory AL amyloidosis","volume":"43","author":"Lebel","year":"2025","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.htct.2026.106482_bib0078","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.3390\/cancers15061710","article-title":"Venetoclax in relapse\/refractory AL amyloidosis-A multicenter international retrospective real-world study","volume":"15","author":"Lebel","year":"2023","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.htct.2026.106482_bib0079","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41408-020-00397-w","article-title":"Venetoclax induces deep hematologic remissions in t(11;14) relapsed\/refractory AL amyloidosis","volume":"11","author":"Premkumar","year":"2021","journal-title":"Blood Cancer J"},{"issue":"Supplement 1","key":"10.1016\/j.htct.2026.106482_bib0080","doi-asserted-by":"crossref","first-page":"7497","DOI":"10.1182\/blood-2025-7497","article-title":"Long-term follow-up of venetoclax therapy in AL amyloidosis","volume":"146","author":"Bhutani","year":"2025","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.htct.2026.106482_bib0081","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1182\/bloodadvances.2018021261","article-title":"Delay treatment of AL amyloidosis at relapse until symptomatic: devil is in the details","volume":"3","author":"Sanchorawala","year":"2019","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.htct.2026.106482_bib0082","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1182\/bloodadvances.2018021253","article-title":"When should treatment of AL amyloidosis start at relapse? Early, to prevent organ progression","volume":"3","author":"Palladini","year":"2019","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.htct.2026.106482_bib0083","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1182\/blood-2017-04-780544","article-title":"Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies","volume":"131","author":"Palladini","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.htct.2026.106482_bib0084","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/13506129.2022.2093635","article-title":"Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group","volume":"30","author":"Wechalekar","year":"2023","journal-title":"Amyloid"},{"issue":"Supplement 1","key":"10.1016\/j.htct.2026.106482_bib0085","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1182\/blood-2021-152675","article-title":"Systemic light chain amyloidosis across Europe: key outcomes from a retrospective study of 4500 patients","volume":"138","author":"Palladini","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.htct.2026.106482_bib0086","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2024-003124","article-title":"Diagnostic pathways, cardiac manifestations and outcomes in light chain amyloidosis: analysis of a US claims database","volume":"12","author":"Lyons","year":"2025","journal-title":"Open Heart"},{"issue":"10","key":"10.1016\/j.htct.2026.106482_bib0087","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1002\/ajh.25915","article-title":"Localized immunoglobulin light chain amyloidosis: novel insights including prognostic factors for local progression","volume":"95","author":"Basset","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.htct.2026.106482_bib0088","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1002253","article-title":"Localized light chain amyloidosis: a self-limited plasmacytic B-cell lymphoproliferative disorder","volume":"12","author":"Mart\u00ednez","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.htct.2026.106482_bib0089","article-title":"The story of localized amyloidosis: something old and something new - a case series","volume":"13","author":"Shah","year":"2025","journal-title":"J Investig Med High Impact Case Rep"},{"issue":"21","key":"10.1016\/j.htct.2026.106482_bib0090","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1182\/blood.V122.21.3143.3143","article-title":"Risk of progression of localised amyloidosis to systemic disease In 606 patients over 30 years","volume":"122","author":"Mahmood","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.htct.2026.106482_bib0091","doi-asserted-by":"crossref","DOI":"10.1002\/hon.70082","article-title":"Presentation and outcomes of Localized immunoglobulin light chain amyloidosis: 14-year experience of an academic center","volume":"43","author":"Dima","year":"2025","journal-title":"Hematol Oncol"}],"container-title":["Hematology, Transfusion and Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2531137926002294?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2531137926002294?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:04:21Z","timestamp":1791475461000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2531137926002294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":91,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2531137926002294"],"URL":"https:\/\/doi.org\/10.1016\/j.htct.2026.106482","relation":{},"ISSN":["2531-1379"],"issn-type":[{"value":"2531-1379","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Brazilian consensus recommendations on the diagnosis and treatment of light chain amyloidosis","name":"articletitle","label":"Article Title"},{"value":"Hematology, Transfusion and Cell Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.htct.2026.106482","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Associa\u00e7\u00e3o Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"106482"}}